Loading... Please wait...


Our Newsletter

SU5416 (Semaxinib) | Flk-1/KDR inhibitor

  • SU5416 (Semaxinib).jpg
  • SU5416 (Semaxinib), 400x400px, png
Catalog #:

Product Description

SU5416 (Semaxinib) is a reversible, ATP-competitive, oxindole-based inhibitor of Flk-1/KDR receptor tyrosine kinase. SU5416 inhibits VEGF-dependent phosphorylation of the Flk-1 receptor in Flk-1-overexpressing NIH 3T3 cells with a IC50 of 1.04 uM. In an ELISA-based assay, SU5416 inhibits autophosphorylation of the Flk-1 receptor at an IC50 of 1.23 uM. [1]

In a mitogenic/proliferation assay in HUVECs, the IC50 of SU5416 is extremely time-dependent, ranging from 1 uM to 40 nM at 48h incubation. These data in conjunction with dose-ranging studies support regimens of less than once-daily dosing of SU5416. [2]

More recent studies have shown that SU5416 is also an agonist of the aryl hydrocarbon receptor (AHR), leading to the generation of regulatory T-cells in vitro. SU5416 also upregulates CYP1A1 and CYP1B1. [3]

Technical information:

Chemical Formula:   C15H14N2O
CAS #:   204005-46-9
Molecular Weight:   238.28
Purity: > 98%
Appearance:   White
Chemical Name:   2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)
Solubility:   Up to 20 mM in DMSO
Synonyms:   SU5416, SU 5416, su-5416, Semaxinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Fong et al., SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res. 1999, 59, 99-106. Pubmed ID: 9892193
2. Mendel et al., The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function. Clin. Cancer Res. 2000, 6, 4848-4858. Pubmed ID: 11156244
3. Mezrich et al., SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation. PLOS One, 2012, 7(9), e44547.

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the SU5416 (Semaxinib) | Flk-1/KDR inhibitor to your wish list.

You Recently Viewed...